Archives

Abstract Number: 678 – GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Presenter: Maria- Victoria MateosSession: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and BeyondDate & Time: Sunday, December 8, 2024 5:45 PM–6:00 PMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis San...

Abstract Number: 676 – Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Presenter: Annemiek Broijl, PhDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and BeyondDate & Time: Sunday, December 8, 2024 5:15 PM–5:30 PMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis San...

Abstract Number: 675 – Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Presenter: Laahn Foster, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and BeyondDate & Time: Sunday, December 8, 2024 5:00 PM–5:15 PMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego...

Abstract Number: 674 – Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Presenter: Pieter Sonneveld, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and BeyondDate & Time: Sunday, December 8, 2024 4:45 PM–5:00 PMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis San...

Abstract Number: 673 – IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Presenter: Gordon Cook, PhD, DScSession: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and BeyondDate & Time: Sunday, December 8, 2024 4:30 PM–4:45 PMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis San...

« Older Entries

Next Entries »

Abstract Number: 678 – GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Abstract Number: 676 – Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Abstract Number: 675 – Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Abstract Number: 674 – Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Abstract Number: 673 – IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Recent Posts

Recent Comments

Categories

Meta